The $26 price valuation set by Zacks Small-Cap Research is a positive signal for MediciNova. However, this valuation is highly dependent on the continued clinical success of the company's assets. If the company's clinical trials show positive results, this could lead to an increase in the stock price. Conversely, if the trials do not meet expectations, the stock price could be negatively affected.